- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alto Neuroscience, Inc.(ANRO)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ANRO
11/20/2026: ANRO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company that develops precision medicines for neuropsychiatric disorders using a proprietary biomarker platform. The company's primary strength lies in its biomarker-driven approach and a diversified clinical pipeline featuring multiple mid-to-late-stage candidates like ALTO-100, ALTO-300, and ALTO-207. Its primary investment growth story centers on redefining psychiatry and achieving key clinical data readouts that could validate its platform. Key risks include clinical trial uncertainty, lack of commercial revenue, and operational losses typical of pre-commercial biotech firms. The stock best suits growth-oriented investors with a high risk tolerance who are willing to monitor upcoming clinical catalysts and financial runway.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Alto offers high potential clinical-stage growth tied to innovative biomarker-driven psychiatry pipelines. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp upside movements around major clinical data readouts and financing announcements. |
| Value investor | Weak fit | As a pre-commercial biotechnology company with ongoing net losses, it lacks traditional value or earnings metrics. |
| Dividend investor | Weak fit | The company does not pay dividends, retaining all capital for drug development. |
| Low-risk investor | Weak fit | High clinical development and regulatory volatility make it unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotechnology stocks frequently experience dramatic price swings based on trial results and news flow. |
| Valuation risk | High | Valuations are driven by clinical potential rather than current earnings or revenue generation. |
| Competition risk (CNS drug development) | Medium / high | The neuropsychiatry space features many competitors developing alternative therapies for depression and schizophrenia. |
| Business quality | Medium | Alto possesses a scientifically rigorous platform, but long-term commercial viability remains unproven. |
| Dividend income | Low / none | No dividend is paid or expected in the foreseeable future. |
| Execution risk | High | Success depends heavily on successful clinical trial execution, patient enrollment, and regulatory approvals. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.02B USD | Price to earnings Ratio - | 1Y Target Price 38.67 |
Price to earnings Ratio - | 1Y Target Price 38.67 | ||
Volume (30-day avg) 669.8K shares | Beta 1.45 | 52 Weeks Range 12.51 - 37.48 | Updated Date 11/21/2026 |
52 Weeks Range 12.51 - 37.48 | Updated Date 11/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.32 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -9.13% | Avg. Invested days 31 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Therapeutic Product Sales & Licensing | Future commercialization of precision psychiatry drug candidates such as ALTO-100, ALTO-300, and ALTO-207, or potential milestone and royalty payments from partnership agreements. | The company currently makes no commercial money and operates entirely on external financing and cash reserves while developing its drug pipeline. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 762.01M | Price to Sales(TTM) - |
Enterprise Value 762.01M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 40.11M | Shares Floating 30.46M |
Shares Outstanding 40.11M | Shares Floating 30.46M | ||
Percent Insiders 4.12 | Percent Institutions 103.28 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

